Efficacy and Safety of Variable-Dose Versus Continuous-Dose Abrocitinib Treatment in Patients with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis - Top-Institutions - MDSpire

Efficacy and Safety of Variable-Dose Versus Continuous-Dose Abrocitinib Treatment in Patients with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis

  • By

  • Jonathan I. Silverberg

  • Eric L. Simpson

  • Saleem A. Farooqui

  • Gary Chan

  • Pinaki Biswas

  • Erman Güler

  • May 20, 2026

  • 0 min

Share

Top Institutions in Dermatology

Brief introduction explaining scope and methodology.

  • #1

    Icahn School of Medicine at Mount Sinai / The Mount Sinai Hospital
    Icahn School of Medicine at Mount Sinai / The Mount Sinai Hospital

    New York, NY

    Key Differentiators

    • Dermatology

  • #2

    Oregon Health & Science University (OHSU)
    Oregon Health & Science University (OHSU)

    Portland, OR

    Key Differentiators

    • Dermatology

  • #3

    Corrona
    Corrona

    Multiple Locations, USA

    Key Differentiators

    • Dermatology

  • #4

    CorEvitas RA Registry
    CorEvitas RA Registry

    Multiple Locations, USA

    Key Differentiators

    • Dermatology

  • #5

    DAMA-S Study
    DAMA-S Study

    Spain, N/A

    Key Differentiators

    • Dermatology

Original Source(s)

Efficacy and Safety of Variable-Dose Versus Continuous-Dose Abrocitinib Treatment in Patients with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis

  • by Jonathan I. Silverberg, Eric L. Simpson, Saleem A. Farooqui, Gary Chan, Pinaki Biswas, Erman Güler

  • May 20, 2026

Related Content

Case Report: Intravenous transplantation of autologous adipose tissue-derived mesenchymal stem cells attenuated atopic dermatitis

Amendment: Dupilumab Alleviates Itching in Various Dermatological Conditions: Insights from Clinical Trials on Atopic Dermatitis, Prurigo Nodularis, and Chronic Spontaneous Urticaria

Medical Oddities: Muscle Memory Before Birth? 

When dad trains offspring gain, bar tricks can end in the OR, guts that linger, empathetic pain, and “natural” immune traps this week.